In subjects with newly diagnosed, high-risk (IPI 3–5) DLBCL, the EPCORE DLBCL-2 study evaluates the safety and preliminary efficacy of epcoritamab in combination with R-CHOP compared to R-CHOP alone. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.